Fatal Temozolomide induced aplastic anemia in a female with Glioblastoma
Multiforme ,A case report and literature review
Temozolomide (TMZ) is a standard of care treatment for Glioblastoma
Multiforme (GBM). We report a fatal outcome of a 55 years old female
with GBM who developed persistent aplastic anemia (AA) while being
treated with TMZ. This case highlights the possibility of a
dose-independent and fatal AA secondary to TMZ.